Clinical Trials Logo

Syndrome X clinical trials

View clinical trials related to Syndrome X.

Filter by:
  • None
  • Page 1

NCT ID: NCT02723903 Recruiting - Syndrome X Clinical Trials

Hierarchical Treatment Based on Somatization Symptom Checklist

Start date: December 2015
Phase: Phase 1/Phase 2
Study type: Interventional

A comparative study is conducted on the patients with suspected coronary artery disease (CAD). The patient will undergo coronary angiography after a somatic symptom scale (SSS) survey is carried out combining with Patient Health Questionnaire (PHQ-9) and Generalized Anxiety Disorder 7-items (GAD-7). Patient is then treated according to the checklist score and coronary angiography result. The efficacy, sensitivity and specificity of the SSS checklist will be evaluated during following up.

NCT ID: NCT02307214 Completed - Clinical trials for Takotsubo Cardiomyopathy

Tako-Tsubo Cardiomyopathy and Cardiac Syndrome X: New Insights Into the Pathophysiology

ENDAUT
Start date: October 2013
Phase: N/A
Study type: Interventional

Tako-Tsubo Cardiomyopathy (TTC) and Cardiac Syndrome X (CSX) are respectively acute and chronic cardiac conditions whose clinical presentation, mimicking the onset of acute myocardial ischemia in absence of epicardial coronary disease, has progressively gained the interest of the scientific community. However, despite significant progress, their underlying pathophysiology, which seems to evoke some similarities, still remains elusive. Endothelial dysfunction and autonomic imbalance have both been individually implied in their puzzling pathogenesis. The investigators plan to conduct our study in a cohort of TTC patients, CSX patients and healthy volunteers with the following primary objective: to assess the response of endothelial function (through the Endopat score) to the autonomic tone activation induced by a 10-minute stress mental test. The assessment of autonomic tone during activation through the evaluation of Spontaneous BaRoreflex Sensitivity (BRS) and its correlation with endothelial function (Endopat score) will represent secondary objectives. Our study will enroll 15 patients with TTC at least six months after the event, 15 patients with classic CSX and 15 healthy volunteers who will serve as control.

NCT ID: NCT00512057 Completed - Syndrome X Clinical Trials

APEX Study: Effects of Allopurinol on Coronary and Peripheral Endothelial Function in Patients With Cardiac Syndrome X

APEX
Start date: June 2008
Phase: Phase 4
Study type: Interventional

Morbidity of patients with cardiac syndrome X (typical anginal-like chest pain and normal coronary arteriograms) is high with continuing episodes of chest pain and frequent hospital readmissions. Management of this syndrome represents a major challenge to the treating physician. Evidence for the important role of endothelial dysfunction and oxidative stress in the pathogenesis of cardiac syndrome X has been recently strengthened by the finding that basal superoxide production predicts future cardiovascular events in this patient group. The investigators have recently shown that high-dose allopurinol abolishes vascular oxidative stress and improves endothelial function in patients with chronic heart failure, which makes allopurinol a prime candidate to reduce oxidative stress in syndrome X. The hypothesis to be tested in this study is whether allopurinol offers dual benefits of improving vascular function and reducing myocardial ischaemia in patients with cardiac syndrome X. This study may discover a novel way to improve endothelial function and anginal symptoms which are often debilitating in these patients.

NCT ID: NCT00190086 Terminated - Syndrome X Clinical Trials

Syndrome X and Endothelial Dysfunction

Start date: January 2001
Phase: Phase 4
Study type: Observational

Cardiac syndrome X is characterized by angina, positve stress test, and patent coronary angiography, and its probable mechanism is microvascular dysfunction associated with endothelial dysfunction. We used brachial artery flow-mediated vasodilation to assess the endothelial function of the patients with syndrome X, coronary artery disease, and controls. Methods: We enrolled 28 patients with syndrome X, 11 healthy volunteers and 11 coronary artery disease patients. All subjects underwent a 2-step brachial artery flow-related vasodilation test: ultrasound artery diameter was measured at rest and after occlusion to assess endothelium-dependent vasodilation and after sublingual nitroglycerin to determine endothelium-independent condition. Serum endothelin-1 assay was performed for all participants. Results: The cardiac syndrome X patients had lower brachial artery dilation ratio (diameter after test/ diameter before test) than controls (1.10 +/- 0.09 versus 1.27 +/- 0.11, p=0.013), but the ratio is still higher than CAD patients (1.10 +/- 0.09 versus 1.02 +/- 0.07, p<0.001). After sublingual nitroglycerin, all 50 subjects had adequate vasodilation. Besides, normal controls have higher endothelin-1 level than the others. We concluded that syndrome X patients have worse endothelial function than healthy control, but patients of CAD had even worse endothelium function than cardiac syndrome X patients. Keywords: Cardiac syndrome X, coronary artery disease, endothelium-dependent vasodilation, endothelium-independent vasodilation, flow-mediated vasodilation, endothelin-1

NCT ID: NCT00001459 Completed - Healthy Clinical Trials

Analysis of Heart Muscle Function in Patients With Heart Disease and Normal Volunteers

Start date: January 1995
Phase: N/A
Study type: Observational

Myocardial ischemia is a heart condition in which not enough blood supply and oxygen reaches the heart muscle. Damage to the major blood vessels of the heart (coronary artery disease), minor blood vessels of the heart (microvascular heart disease), or damage to the heart muscle (hypertrophic cardiomyopathy) can cause myocardial ischemia. Any of theses three conditions can cause patients to experience chest pain and other symptoms as well as cause the heart to function improperly. In order to detect myocardial ischemia researchers can use tests to measure the movement of the walls of the heart. Walls receiving inadequate supplies of blood often move less and occasionally move in the opposite direction. Some of the tests may require patients to receive injections of radioactive tracers. The radioactive material acts to enhance 3 dimensional pictures of the heart and helps to identify areas of ischemia. The purpose of this study is to determine whether 3-dimensional imaging (tomography) with radioactive tracers can provide more important information about heart wall function than routine diagnostic tests.